Leading a revolution in the treatment of kidney diseases.


Treat kidneys, transform lives.

At Purespring, we are leading a revolution in the treatment of kidney diseases. More than 8 million people in the UK and 840 million people globally suffer from chronic kidney disease.

Sadly, many of these patients do not have satisfactory treatment options. Purespring exists to change this current situation by providing transformative treatments for a range of kidney diseases. Making a real difference to patients suffering from these diseases, and the people supporting them, is what motivates us.


Imagine a near future where patients with kidney diseases are empowered with therapies to change the course of their disease.

Therapeutic innovation has been lacking in renal treatments, and patients are in dire need of new options.

Moreover, when patients progress to end-stage renal disease, they are faced with two options, dialysis or kidney transplant, both of which are burdensome, come with complications and adversely affect their quality of life. Our mission is to bring disease-modifying therapies to these patients.

Our therapies will target rare monogenic diseases, as well as much more prevalent common forms of kidney disease. By bringing the power of gene therapy specifically to the kidney, we aim to stop kidney diseases in their tracks, and to do it as soon as possible. Patients suffering from kidney diseases have been faced with unsatisfactory treatment options for many years. At Purespring, we are looking to change the status quo, and to do it now.


The Keys to our Success.

The first gene therapy platform to specifically target kidney diseases.

We understand kidney diseases like nobody else. Based on decades of research from our scientific founder, Professor Moin Saleem, we now understand that the key to unlocking kidney health is the podocyte, a cell type vital to kidney function and health. This is why we are developing a proprietary platform and novel treatments focused on targeting the podocyte.

Our keys to success will be our podocyte-specific, gene therapy viral vector (capsid), our targeted genetic elements (kidney-specific promoters), our specific route of administration, and our in-house panel of analytics to ensure that we manufacture the best product.


Your kidney care, in good hands.

The Purespring team is starting with the future, now.

We are a young company drawing on experience from industry and business veterans. We are led by the best people in their fields. Purespring is proudly created and funded by Syncona, a life science investment company with a proven track-record in building innovative gene therapy companies.

If you would like to become a Purespringer, join us on our mission to make a difference to patients suffering from kidney diseases.